Medical eponyms are diseases, disorders, or syndromes named after people, and occasionally places or things. Eponyms are widely used and new ones continue to be coined, although some physicians argue against their use.
Eponyms are most typically named after the physician or researcher who first described the condition, such as Parkinson's disease, after James Parkinson (1755-1824) or Alzheimer's disease, after Alois Alzheimer (1864–1915). Some diseases are commonly known by a famous patient's name, such as Lou Gehrig disease, although amyotrophic lateral sclerosis is the clinical name. A few clinical names come from a patient's name, such as Hartnup disease (formally pellagra-like dermatosis with transitory cerebellar ataxia), named for a family with this hereditary disease. Sometimes conditions are named after multiple physicians or scientists, such as Waterhouse–Friderichsen syndrome. Lyme disease is named for two towns where the symptoms were first identified. The eponym may even be a fictional character with no direct relationship to the disease. For example, Munchausen syndrome was coined because, like Baron von Munchausen, "the persons affected have always travelled widely, and their stories, like those attributed to him, are both dramatic and untrue."
Eponyms are widely used in medicine and continue to be coined. The names may be easier to remember than by their pathological description: compare Hodgkin lymphoma and nodular sclerosing, mixed cellularity, lymphocyte depleted, lymphocyte rich, and nodular lymphocyte-predominant lymphomas. Eponyms have replaced some older disease names which were problematic in various ways: "Mongolism" is racist, while Down syndrome is neutral; leprosy has centuries of stigmatizing connotations, while Hansen's disease does not, so was promoted as a more human name. And some names are used for multiple diseases: there are twelve named for Harvey Cushing.
Some eponyms have been replaced. For example, Reiter's syndrome, named after a Nazi medical war criminal, is now called reactive arthritis.
All agree that eponyms are widely used and unlikely to change quickly.